NOT-AI-14-022: Notice of Change in PAR-13-250 NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)

Notice of Change in PAR-13-250 "NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)"

Notice Number: NOT-AI-14-022

Key Dates
Release Date: January 15, 2014

Related Announcements
PAR-13-250

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is to inform potential applicants that the NIAID is revising PAR-13-250, “NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44),” to clarify the exception of Fast-Track applications to the list of 'NOT supported' areas in the Commercialization Plan section of the FOA.

Part 2. Section I. Funding Opportunity Description

Commercialization Plan
Current Language
Awards made under the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) FOA will NOT provide support for:

Modified Language
Awards made under the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) FOA (except Fast-Track applications) will NOT provide support for:

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Natalia Kruchinin Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-496-8666
Email: kruchininn@niaid.nih.gov